RECQL and plasma cell myeloma: In a subsequent study, RECQ1 overexpression in multiple myeloma cells conferred resistance against the DNA alkylating drug melphalan and proteasome inhibitor bortezomib, and high expression of RECQ1 associated with poor prognosis in multiple myeloma patients treated with high dose melphalan [61].